Abstract
Purpose
To assess the association between duration of symptoms and main prognostic factors of invasive epithelial ovarian cancer (EOC).
Methods
The data of all histologically confirmed EOC patients diagnosed in Israel during the period 1994–1999 (n = 1,005) were retrieved from discharge summaries and admission records. Of the 371 (36.9%) patients with known presenting symptoms, the durations of 187 (50.4%) were recorded.
Results
The most common presenting symptoms were abdominal pain (65.2%). The percentage of patients with three or more symptoms increased significantly with stage (P = 0.001). No statistically significant association between duration of symptoms and prognostic factors was found.
Conclusion
Our findings did not show an association between duration of symptoms and prognostic factors in EOC patients and may indicate that prognosis is not a function of delay in diagnosis.
Similar content being viewed by others
References
Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36
Berkenblit A, Cannistra SA (2005) Advances in the management of epithelial ovarian cancer. J Reprod Med 50:426–438
Eisenhauer EA, Gore M, Neijt JP (1999) Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 10:S9–S15. doi:10.1023/A:1008343015697
Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA et al (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413–1416. doi:10.1056/NEJM199611073351901
Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, Tsuji S et al (1998) Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4:235–240
Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL et al (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260–2265. doi:10.1001/jama.283.17.2260
Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U et al (2002) National Israeli study of ovarian cancer effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20:463–466. doi:10.1200/JCO.20.2.463
Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187–2195. doi:10.1002/cncr.11310
Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J et al (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104:1004–1012. doi:10.1002/cncr.21276
Guppy AE, Nathan PD, Rustin GJ (2005) Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 17:399–411. doi:10.1016/j.clon.2005.05.009
Vine MF, Calingaert B, Berchuck A, Schildkraut JM (2003) Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol 90:75–82. doi:10.1016/S0090-8258(03)00175-6
Neal RD, Allgar VL (2005) Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the “National survey of NHS patients: cancer”. Br J Cancer 92:1971–1975
Goff BA, Mandel LS, Melancon CH, Muntz AG (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705–2712
Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Urban N (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109:221–227. doi:10.1002/cncr.22371
Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005) Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 88:31–37. doi:10.1016/j.ijgo.2004.09.008
Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS (2005) Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 104:1398–1407. doi:10.1002/cncr.21310
Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S (2001) Symptoms of ovarian cancer. Obstet Gynecol 98:212–217. doi:10.1016/S0029-7844(01)01457-0
Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U et al (2001) National Israel ovarian cancer study group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 45:235–240. doi:10.1056/NEJM200107263450401
Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R et al (2003) Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 89:494–498. doi:10.1016/S0090-8258(03)00152-5
Wikborn C, Pettersson F, Moberg PJ (1996) Delay in diagnosis of epithelial ovarian cancer. Int J Gynaecol Obstet 52:263–267
Goff BA, Mandel L, Muntz HG, Melancon CH (2000) Ovarian carcinoma diagnosis. Cancer 89:2068–2075
Fruchter RG, Boyce J (1981) Delays in diagnosis and stage of disease in gynecologic cancer. Cancer Detect Prev 4:481–486
Smith EM, Anderson B (1985) The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 56:2727–2732
Flam F, Einhorn N (1988) Sjovall K: Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 27:53–57
Kirwan JM, Tincello DG, Herod JJO, Frost O, Kingston RE (2002) Effect of delays in primary care referral on survival of women with epithelial ovarian cancer. Br Med J 324:148–151
Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF (2005) Presenting symptoms of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol 45:211–214
Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 339:59–61
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature 1:27–33
Tammela J, Odunsi K (2004) Gene expression and prognostic significance in ovarian cancer. Minerva Ginecol 56:495–502
Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Lege F et al (2002) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205–1211
Conflict of interest statement
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Appendix
Appendix
The members of the National Israel Ovarian Cancer Group are as follows:
Shmuel Anderman, MD, Marco Alteras, MD, Shaul Anteby, MD, Jack Atad, MD, Amiram Avni, MD, Amiram Bar-Am, MD, Dan Beck, MD, Uzi Beller, MD, Gilad Ben-Baruch, MD, Yehuda Ben-David, MD, Izhar Ben-Shlomo, MD, Haim Biran, MD, Moshe Ben Ami, MD, Angela Chetrit, BSc, Shlomit Cohen, MD, Shulamit Cohen, MD, Ram Dgani, MD, Yehudit Fishler, MD, Ami Fishman, MD, Eitan Friedman, MD, Ofer Gemer, MD, Ruth Gershoni, MD, Reuvit Halperin, MD, Galit Hirsh-Yechezkel, MD, David Idelman, MD, Rafael Katan, MD, Yuri Kopilovic, MD, Efrat Lahad, MD, Liat Lerner-Geva, MD, Hanoch Levavi, MD, Tally Levi, MD Albert Levit, MD, Beatriz Lifschitz-Mercer, MD, Flora Lubin, MSc R.D., Zohar Leviatan, MD, Jacob Marcovich, MD, Joseph Menczer, MD, Baruch Modan, MD (Chairman, diseased), Hedva Nitzan, RN, MPH, Moshe Oetinger, MD, Tamar Perez, MD, Benjamin Piura, MD, David Schneider, MD, Mariana Shteiner, MD, Zion Tal, MD, Chaim Yaffe, MD, Ilana Yanai, MD, Shifra Zohar, RN, BA.
Rights and permissions
About this article
Cite this article
Menczer, J., Chetrit, A., Sadetzki, S. et al. The effect of symptom duration in epithelial ovarian cancer on prognostic factors. Arch Gynecol Obstet 279, 797–801 (2009). https://doi.org/10.1007/s00404-008-0814-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-008-0814-1